A phase 2a randomised, double-blind, placebo-controlled, parallel-group, add-on clinical trial of ebselen (SPI-1005) as a novel treatment for mania or hypomania

RATIONALE: Lithium is an effective prophylactic and anti-manic treatment in bipolar disorder; however, its use is declining through perceived poor tolerance and toxicity. Lithium inhibits inositol monophosphatase (IMPase), a probable key therapeutic mechanism. The anti-inflammatory drug, ebselen, al...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharpley, Ann L, Williams, Clare, Holder, Adele A, Godlewska, Beata R, Singh, Nisha, Shanyinde, Milensu, MacDonald, Orla, Cowen, Philip J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683468/
https://www.ncbi.nlm.nih.gov/pubmed/32909076
http://dx.doi.org/10.1007/s00213-020-05654-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683468/
https://www.ncbi.nlm.nih.gov/pubmed/32909076
http://dx.doi.org/10.1007/s00213-020-05654-1

Ejemplares similares